Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Chief Financial Officer | February 17, 2021 | February 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Trevi Therapeutics, Inc.
Report date February 17, 2021 · Filed February 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.21 · Expires 2031-02-16 | Direct | 80,000 |
Reported balance
After 2021-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-17 · Grant · Acquired 80,000 · Balance 80,000 F1: This option was granted on February 17, 2021. The 80,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 17, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 17, 2021. The 80,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 17, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2021 Filed Feb 19, 2021 21:15 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0000899243-21-007378 · doc4.xml · derivative · entry 1 Seiter Christopher · CIK 0001774627 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: This option was granted on February 17, 2021. The 80,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 17, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 17, 2025. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:15 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-20-004872 · doc4.xml · derivative · entry 1 Seiter Christopher · CIK 0001774627 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2020. The 65,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 21:11 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.12 | $0.00 |
DisclosureSEC source: 0000899243-19-015609 · doc4.xml · derivative · entry 1 Seiter Christopher · CIK 0001774627 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2019. The 50,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on June 3, 2020 and as to the remaining 75% of the shares in equal monthly installments thereafter through June 3, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.